Metformin Use in Patients with Liver Dysfunction

Introduction to Metformin Therapy

• The American Association for the Study of Liver Diseases recommends that metformin can be safely used in patients with compensated cirrhosis and preserved kidney function, but it is contraindicated in decompensated cirrhosis, especially with concomitant kidney dysfunction, due to the risk of lactic acidosis 1, 2

Key Principles of Metformin Administration

• The European Association for the Study of the Liver states that metformin is permitted in adults with compensated cirrhosis, provided kidney function is preserved (eGFR ≥45 ml/min/1.73 m²) 1, 2
• Regular monitoring of kidney function every 3-6 months is necessary, as patients with liver diseases have an increased risk of worsening kidney function 3
• Metformin improves ALT levels and may provide a protective effect against hepatocellular carcinoma based on observational studies 1, 2

Metformin Contraindications

• The American Association for the Study of Liver Diseases advises that metformin is contraindicated in decompensated cirrhosis (Child-Pugh class B-C), especially with concomitant kidney dysfunction 1, 2
• The risk of metformin-associated lactic acidosis significantly increases with liver decompensation due to impaired oxidative phosphorylation and reduced lactate clearance 1, 2

Temporary Discontinuation of Metformin

• Metformin should be immediately discontinued in the event of acute conditions, even in patients with compensated cirrhosis, including serious infections, sepsis, dehydration, vomiting, diarrhea, acute heart failure with hypoperfusion/hypoxemia, and intestinal obstruction 2, 4, 5

Decision-Making Algorithm

• Step 1: Assess the degree of liver dysfunction (Child-Pugh class) - Class A (compensated) allows metformin use, while Class B-C (decompensated) contraindicates it 1, 2
• Step 2: Evaluate kidney function (eGFR) - eGFR ≥45 ml/min/1.73 m² allows standard dosing, eGFR 30-44 ml/min/1.73 m² requires dose adjustment, and eGFR <30 ml/min/1.73 m² contraindicates metformin 1, 2, 3

Monitoring and Patient Education

• Regular monitoring of eGFR every 3-6 months and patient education on the rules for discontinuing metformin during acute illnesses are crucial 3, 4

Contraindications to Metformin Use

Absolute Contraindications

• Metformin is renally excreted, and clearance is proportional to GFR, making accumulation inevitable below the threshold of eGFR <30 mL/min/1.73 m², according to the American Journal of Kidney Diseases 6

Situations Requiring Immediate Discontinuation

• Discontinue metformin during any hospitalization, acute illness, or condition that may compromise renal or hepatic function, as recommended by Diabetes Care 7
• Implement "sick-day rules" where patients are educated to hold metformin when acutely ill at home, as suggested by the American Journal of Kidney Diseases 6

Relative Contraindications and Cautions

• The FDA recommends assessing benefits and risks of continuing treatment when eGFR falls below 45 mL/min/1.73 m², according to Diabetes Care 8
• Use metformin with caution in patients with congestive heart failure due to increased lactic acidosis risk, as noted by Diabetes Care 7

Metformin Effects on the Liver in Patients with Pre-existing Liver Disease

Beneficial Effects in Compensated Liver Disease

• Long-term metformin use (>6 years) in diabetic patients with NASH and advanced fibrosis significantly reduces overall mortality, liver transplantation, and hepatocellular carcinoma risk 9, 10
• Metformin reduces the risk of decompensated cirrhosis and HCC in patients with NAFLD-associated Child-Pugh class A cirrhosis 9, 10
• Metformin lengthens survival and decreases the risk of decompensated cirrhosis in patients with NAFLD-associated compensated cirrhosis 10

Mechanism of Hepatic Benefits

• Metformin suppresses hepatic glucose production, inhibits hepatic fat accumulation, and activates adenosine monophosphate-activated protein kinase (AMPK) 9
• Metformin decreases expression of tumor necrosis factor-α and suppresses gluconeogenesis while stimulating glycolysis 9

Limitations on Histological Improvement

• Despite theoretical benefits, metformin has little or no effect on liver histology in NASH 9, 10, 11
• Randomized controlled studies showed that metformin did not improve histological findings in the liver, insulin resistance, or liver enzyme levels compared with controls 9, 10, 11

Situations Requiring Immediate Discontinuation

• Metformin should be temporarily discontinued with any acute illness associated with dehydration or hypoxemia 12

Common Pitfalls and Caveats

• Metformin should not be discontinued in individuals with compensated cirrhosis unless discontinuation is required due to hepatic decompensation or renal failure, as this could increase mortality 13